Expression of Smad1 is directly associated with mesangial matrix expansion in rat diabetic nephropathy. 2006

Takeshi Matsubara, and Hideharu Abe, and Hidenori Arai, and Kojiro Nagai, and Akira Mima, and Hiroshi Kanamori, and Eriko Sumi, and Toshikazu Takahashi, and Motokazu Matsuura, and Noriyuki Iehara, and Atsushi Fukatsu, and Toru Kita, and Toshio Doi
Department of Nephrology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Diabetic nephropathy is the leading cause of end-stage renal disease, and glomerular mesangial matrix expansion is the hallmark in diabetic nephropathy. However, the precise mechanism for the development of mesangial matrix expansion has remained unknown. The key component involved in mesangial matrix expansion is type IV collagen (Col4). Recently, we have reported that Smad1 transcriptionally regulates expression of Col4 under diabetic conditions in vitro. Here we show that this direct regulator of Col4 also plays a crucial role for mesangial matrix expansion in vivo. Streptozotocin-induced diabetic rats are the model of incipient diabetic nephropathy, and showed various levels of mesangial matrix expansion at 24 weeks. The glomerular expression of Smad1 was significantly increased in diabetic rats with more mesangial matrix expansion by Western blot and immunohistochemical analysis. Furthermore, the glomerular expression of Smad1 was closely correlated with the glomerular expression of Col4 and smooth muscle alpha actin (alpha-SMA), while albuminuria or glomerular filtration rate was not correlated with mesangial matrix expansion. We also found that urinary excretion of Smad1 was closely associated with the severity of mesangial matrix expansion. In cultured mesangial cells expression of Smad1 upregulated the transcriptional activity of key molecules in mesangial matrix expansion, such as Col4 and alpha-SMA. These data indicate the critical involvement of Smad1 in mesangial matrix expansion in the early phase of diabetic nephropathy. Our data imply that urinary Smad1 might be a representative diagnostic marker for mesangial matrix expansion in diabetic nephropathy.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D007678 Kidney Glomerulus A cluster of convoluted capillaries beginning at each nephric tubule in the kidney and held together by connective tissue. Glomerulus, Kidney
D008297 Male Males
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003921 Diabetes Mellitus, Experimental Diabetes mellitus induced experimentally by administration of various diabetogenic agents or by PANCREATECTOMY. Alloxan Diabetes,Streptozocin Diabetes,Streptozotocin Diabetes,Experimental Diabetes Mellitus,Diabete, Streptozocin,Diabetes, Alloxan,Diabetes, Streptozocin,Diabetes, Streptozotocin,Streptozocin Diabete
D003928 Diabetic Nephropathies KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE. Diabetic Glomerulosclerosis,Glomerulosclerosis, Diabetic,Diabetic Kidney Disease,Diabetic Nephropathy,Intracapillary Glomerulosclerosis,Kimmelstiel-Wilson Disease,Kimmelstiel-Wilson Syndrome,Nodular Glomerulosclerosis,Diabetic Kidney Diseases,Glomerulosclerosis, Nodular,Kidney Disease, Diabetic,Kidney Diseases, Diabetic,Kimmelstiel Wilson Disease,Kimmelstiel Wilson Syndrome,Nephropathies, Diabetic,Nephropathy, Diabetic,Syndrome, Kimmelstiel-Wilson
D005920 Glomerular Mesangium The thin membranous structure supporting the adjoining glomerular capillaries. It is composed of GLOMERULAR MESANGIAL CELLS and their EXTRACELLULAR MATRIX. Mesangium, Glomerular,Mesangial Extracellular Matrix,Extracellular Matrices, Mesangial,Extracellular Matrix, Mesangial,Glomerular Mesangiums,Matrices, Mesangial Extracellular,Matrix, Mesangial Extracellular,Mesangial Extracellular Matrices,Mesangiums, Glomerular
D000199 Actins Filamentous proteins that are the main constituent of the thin filaments of muscle fibers. The filaments (known also as filamentous or F-actin) can be dissociated into their globular subunits; each subunit is composed of a single polypeptide 375 amino acids long. This is known as globular or G-actin. In conjunction with MYOSINS, actin is responsible for the contraction and relaxation of muscle. F-Actin,G-Actin,Actin,Isoactin,N-Actin,alpha-Actin,alpha-Isoactin,beta-Actin,gamma-Actin,F Actin,G Actin,N Actin,alpha Actin,alpha Isoactin,beta Actin,gamma Actin
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Takeshi Matsubara, and Hideharu Abe, and Hidenori Arai, and Kojiro Nagai, and Akira Mima, and Hiroshi Kanamori, and Eriko Sumi, and Toshikazu Takahashi, and Motokazu Matsuura, and Noriyuki Iehara, and Atsushi Fukatsu, and Toru Kita, and Toshio Doi
April 1995, The Western journal of medicine,
Takeshi Matsubara, and Hideharu Abe, and Hidenori Arai, and Kojiro Nagai, and Akira Mima, and Hiroshi Kanamori, and Eriko Sumi, and Toshikazu Takahashi, and Motokazu Matsuura, and Noriyuki Iehara, and Atsushi Fukatsu, and Toru Kita, and Toshio Doi
July 2010, American journal of physiology. Renal physiology,
Takeshi Matsubara, and Hideharu Abe, and Hidenori Arai, and Kojiro Nagai, and Akira Mima, and Hiroshi Kanamori, and Eriko Sumi, and Toshikazu Takahashi, and Motokazu Matsuura, and Noriyuki Iehara, and Atsushi Fukatsu, and Toru Kita, and Toshio Doi
June 2017, American journal of physiology. Renal physiology,
Takeshi Matsubara, and Hideharu Abe, and Hidenori Arai, and Kojiro Nagai, and Akira Mima, and Hiroshi Kanamori, and Eriko Sumi, and Toshikazu Takahashi, and Motokazu Matsuura, and Noriyuki Iehara, and Atsushi Fukatsu, and Toru Kita, and Toshio Doi
January 2012, Nephron. Clinical practice,
Takeshi Matsubara, and Hideharu Abe, and Hidenori Arai, and Kojiro Nagai, and Akira Mima, and Hiroshi Kanamori, and Eriko Sumi, and Toshikazu Takahashi, and Motokazu Matsuura, and Noriyuki Iehara, and Atsushi Fukatsu, and Toru Kita, and Toshio Doi
January 2001, Journal of nephrology,
Takeshi Matsubara, and Hideharu Abe, and Hidenori Arai, and Kojiro Nagai, and Akira Mima, and Hiroshi Kanamori, and Eriko Sumi, and Toshikazu Takahashi, and Motokazu Matsuura, and Noriyuki Iehara, and Atsushi Fukatsu, and Toru Kita, and Toshio Doi
August 1995, Kidney international,
Takeshi Matsubara, and Hideharu Abe, and Hidenori Arai, and Kojiro Nagai, and Akira Mima, and Hiroshi Kanamori, and Eriko Sumi, and Toshikazu Takahashi, and Motokazu Matsuura, and Noriyuki Iehara, and Atsushi Fukatsu, and Toru Kita, and Toshio Doi
September 2013, Diabetologia,
Takeshi Matsubara, and Hideharu Abe, and Hidenori Arai, and Kojiro Nagai, and Akira Mima, and Hiroshi Kanamori, and Eriko Sumi, and Toshikazu Takahashi, and Motokazu Matsuura, and Noriyuki Iehara, and Atsushi Fukatsu, and Toru Kita, and Toshio Doi
August 2022, Journal of biological engineering,
Takeshi Matsubara, and Hideharu Abe, and Hidenori Arai, and Kojiro Nagai, and Akira Mima, and Hiroshi Kanamori, and Eriko Sumi, and Toshikazu Takahashi, and Motokazu Matsuura, and Noriyuki Iehara, and Atsushi Fukatsu, and Toru Kita, and Toshio Doi
April 2018, Oncotarget,
Takeshi Matsubara, and Hideharu Abe, and Hidenori Arai, and Kojiro Nagai, and Akira Mima, and Hiroshi Kanamori, and Eriko Sumi, and Toshikazu Takahashi, and Motokazu Matsuura, and Noriyuki Iehara, and Atsushi Fukatsu, and Toru Kita, and Toshio Doi
March 2019, Life sciences,
Copied contents to your clipboard!